Editas Medicine/$EDIT
1D1W1MYTD1Y5YMAX
Capital at risk
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
- Ticker
- $EDIT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 87
- Headquarters
- Cambridge, United States
- Website
- www.editasmedicine.com
Editas Medicine Metrics
BasicAdvanced
$415M
-
-$0.73
2.06
-
Price and volume
Market cap
$415M
Beta
2.06
52-week high
$4.54
52-week low
$1.66
Average daily volume
3M
Financial strength
Current ratio
3.187
Quick ratio
3.133
Long term debt to equity
0.085
Total debt to equity
0.147
Interest coverage (TTM)
-20.52%
Profitability
EBITDA (TTM)
-81.035
Gross margin (TTM)
-80.74%
Net profit margin (TTM)
-157.32%
Operating margin (TTM)
-177.56%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-23.29%
Return on equity (TTM)
-118.82%
Valuation
Price to revenue (TTM)
5.813
Price to book
3.94
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
-2.267
Free cash flow yield (TTM)
-44.12%
Free cash flow per share (TTM)
-1.191
Growth
Revenue change (TTM)
20.83%
Earnings per share change (TTM)
-74.35%
3-year revenue growth (CAGR)
34.51%
10-year revenue growth (CAGR)
23.59%
3-year earnings per share growth (CAGR)
-37.29%
10-year earnings per share growth (CAGR)
-14.71%
What the Analysts think about Editas Medicine
Analyst ratings (Buy, Hold, Sell) for Editas Medicine stock.
Analyst projections of the future price of Editas Medicine stock.
Bulls say / Bears say
Preclinical results give EDIT-401 a strong efficacy signal: a single dose cut LDL-C, Lp(a) and ApoB by about 90% or more in non-human primates, with no adverse clinical observations at 1.5 mg/kg. If replicated in people, targeting several cardiovascular risk markers with one treatment could support a differentiated product. (GlobeNewswire)
The programme has received positive pre-IND feedback from the FDA, and Editas says it is progressing an Australian Phase 1/2 study with first dosing targeted for 2026 and safety data expected in the first quarter of 2027. That gives the stock a clear near-term clinical catalyst after years of preclinical work. (GlobeNewswire, The Lincolnian Online)
Cash of $211.6m at the end of June, boosted by the May financing, is expected to fund operations and capital needs into the second half of 2028. This should let Editas reach early clinical milestones without an immediate funding gap. (GlobeNewswire)
EDIT-401 has not yet shown efficacy or safety in humans: the current evidence is from non-human primates, while the first cohort’s safety readout is only expected in the first quarter of 2027. Australian ethics clearance is still being worked through, so the planned 2026 dosing date remains execution-dependent. (GlobeNewswire, The Lincolnian Online)
Editas ended the RUBY reni-cel study early after reassessing its clinical priorities, despite the reported activity in sickle-cell disease. The company is now concentrating resources on EDIT-401, with its in-vivo blood-disorder programme still at discovery stage, increasing dependence on one unproven asset. (New England Journal of Medicine, The Lincolnian Online)
The May equity financing raised $116.9m net through 55.6m new shares and warrants, so funding the programme has already diluted shareholders and could create more dilution if the warrants are exercised. Q2 revenue was $11.9m and was helped by recognising deferred BMS revenue, rather than product sales, leaving the company reliant on capital and collaborations. (Last10K, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Editas Medicine Financial Performance
Revenues and expenses
Editas Medicine Earnings Performance
Company profitability
Upcoming events
No upcoming events
Editas Medicine News
AllArticlesVideos
Funds containing Editas Medicine
AllUSDEURGBP
Fund name | Fund size | $EDIT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
iShares Healthcare Innovation£DRDR | £1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.